#priMe infants to stop TB
Tuberculosis (TB) is one of the top 10 causes of death worldwide. An estimated 10 million people fell ill with TB in 2018 with approximately 1.5 million dying from the disease. In children, BCG vaccination can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis. Ultimately, to interrupt transmission of the disease, highly contagious pulmonary forms of TB also need to be targeted by vaccination. The priMe project evaluates the efficacy and safety of a new vaccine candidate against TB.
In 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global emergency. Approx. 1.7 billion people are infected and 10 million people are estimated to have fallen ill with TB in 2017. In the same year approx. 1.5 million died because of TB; among them 205,000 children (aged 0-14 years). South Africa and other Sub-Saharan countries belong to the group of “high-burden” TB countries with an estimated total incidence of 301,000 TB cases in 2018 in South Africa alone.
In children BCG can protect against, or at least ameliorate, severe forms of systemic TB, particularly TB meningitis.
VPM1002 is an innovative live vaccine against TB, based on the well-known Mycobacterium bovis (M. bovis) Bacille Calmette-Guérin (BCG) strain which has been administered approximately 4 billion times worldwide.
The genetic modifications of VPM1002, namely introduction of listeriolysin while simultaneously deleting the gene for urease C in the BCG genome, are aiming for better recognition by the host immune system.
News and Press
VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa.
The pivotal phase III infant vaccine trial was accepted by the African Vaccine Regulatory Forum (AVAREF) for a joint review process. The meeting has taken place from 22-24th of January 2020 in Nairobi, Kenya.